You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
云顶新耀(01952.HK):NeflgArd关键性3期临床试验部分获良好结果
阿思达克 11-10 09:04
云顶新耀(01952.HK)公布,其合作夥伴Calliditas Therapeutics报告了全球3期临床试验NefIgArd A部分获得良好结果,该试验分析了Nefecon对比安慰剂治疗199例原发性IgA肾病(「IgAN」)患者的疗效。

该试验达到了其主要目标,结果显示在治疗9个月後,患者的尿蛋白肌酐比率(或蛋白尿)在统计学上显着降低,在治疗12个月後,有了显着的持续性改善。该试验还达到了关键的次要终点,显示治疗9个月後,即与安慰剂相比,患者肾小球滤过率(eGFR)估计值存在统计学上的显着差异。

疗效资料也表明,在与进展为终末期肾病(ESRD)相关的关键因素上具有显着且有益的效果。此外,结果显示Nefecon的耐受性普遍良好。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account